In Q4'25, ABBV's total operating expenses reached $6.47B USD, with R&D expenses at $2.58B USD and SG&A expenses at $3.90B USD, marking a notable increase from the prior quarter and reflecting heightened investments in research and administrative functions. Over the period from Q1'23 to Q4'25, R&D expenses exhibited an overall upward trend, starting at $2.29B USD and rising steadily to $2.58B USD, with a brief dip in Q2'23-Q3'23 before consistent growth, including a sharp anomaly in Q4'24 at $6.77B USD possibly due to one-time charges. SG&A expenses remained relatively stable around $3.2B-$3.4B USD through 2023 and early 2024, before surging to $4.21B USD in Q3'24 and climbing further to $3.90B USD by Q4'25, indicating expanding operational scale; the stacked bar chart highlights SG&A as the dominant component, comprising over 60% of total expenses in most quarters.